Cointime

Cyteir Therapeutics

company

About

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

  • 11 - 50

Highlights

Total Funding Amount
$82M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Grant
Last Funding Money Raised
$2M
Industries
Biopharma,Biotechnology,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
11 - 50
Operating Status
Active

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$82M
Cyteir Therapeutics has raised a total of $82M in funding over 2 rounds. Their latest funding was raised on Feb 11, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 11, 2021 Series C $80M 1 Ample Plus Fund — Detail
Jun 29, 2016 Grant $2M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Cyteir Therapeutics is funded by 2 investors. Ample Plus Fund and National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
Ample Plus Fund Yes Series C
National Institutes of Health — Grant
Cointime
เนื้อหา
บริษัท